Timing of infliximab and adalimumab initiation despite methotrexate in children with chronic non-infectious anterior uveitis.

Autor: McCracken C; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA., Yeh S; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.; Department of Ophthalmology, Emory University School of Medicine, Atlanta, GA, USA., Jenkins K; Children's Healthcare of Atlanta, Atlanta, GA, USA., Travers C; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA., Stryker D; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA., Tommasello S; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA., Rouster-Stevens KA; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.; Children's Healthcare of Atlanta, Atlanta, GA, USA., Lambert SR; Department of Ophthalmology, Stanford University, Stanford, GA, USA., Prahalad S; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.; Children's Healthcare of Atlanta, Atlanta, GA, USA.; Department of Genetics, Emory University School of Medicine, Atlanta, GA, USA., Drews-Botsch C; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.; Department of Ophthalmology, Emory University School of Medicine, Atlanta, GA, USA.; Rollins School of Public Health, Emory University, Atlanta, GA, USA., Angeles-Han ST; Division of Rheumatology, Cincinnati Children's Hospital Medical Center and Department of Pediatrics, University of Cincinnati, Cincinnati, OH, USA. Sheila.Angeles-Han@cchmc.org.
Jazyk: angličtina
Zdroj: Eye (London, England) [Eye (Lond)] 2019 Apr; Vol. 33 (4), pp. 629-639. Date of Electronic Publication: 2018 Nov 28.
DOI: 10.1038/s41433-018-0283-0
Abstrakt: Aims: Methotrexate (MTX) is standard treatment in pediatric chronic anterior uveitis (CAU). Addition of tumor necrosis factor-α inhibitors (TNFi) is often needed. We describe the timing and risk factors for TNFi use in children with CAU on MTX.
Methods: In this retrospective study, we reviewed 51 records, and 46 met inclusion criteria. Primary outcome was the addition of TNFi due to active CAU per Standardization of Uveitis Nomenclature criteria. Time to TNFi and factors associated with their addition were assessed using survival analysis models.
Results: Of 46 children treated with MTX for uveitis (36 juvenile idiopathic arthritis-associated uveitis, 10 idiopathic CAU), 72% had ocular complications. MTX was started a median of 5.0 months, and TNFi 43 months from uveitis diagnosis. Kaplan-Meier estimates suggest that cumulatively, 12% (95% CI: 4-23%) start TNFi within 6 months of MTX, 21% (12-37%) within 1 year, and 39% (24-54%) within 2 years. On Cox Proportional Hazard regression analysis, children with idiopathic CAU required TNFi earlier in their uveitis course (at 3 months (Hazard Ratio 6.06; 95% confidence interval (1.25-29.41))). Females appeared less likely to require TNFi early. Children treated in 2012 and later were more likely to receive TNFi earlier than those treated before 2012.
Conclusion: Little is known about optimal time to initiate treatment or factors associated with the need to add TNFi in children on MTX. Children with idiopathic CAU and males required TNFi earlier in their course. Factors associated with these potential risk factors for TNFi warrant further investigation.
Databáze: MEDLINE
Externí odkaz: